Does remission of renal disease associated with antihypertensive treatment exist?

被引:2
作者
Cravedi, Paolo [1 ]
Ruggenenti, Piero [1 ]
Remuzzi, Giuseppe [1 ]
机构
[1] Mario Negri Inst Pharmacol Res, Negri Bergamo Labs, I-24125 Bergamo, Italy
关键词
D O I
10.1007/s11906-007-0028-0
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In diabetic and nondiabetic chronic nephropathies, high blood pressure and urinary loss of proteins represent major determinants of progressive renal function decline. Reducing blood pressure with drugs that inhibit the renin-angiotensin system also lowers glomerular hypertension and ameliorates glomerular sieving properties, thus reducing proteinuria. Reducing urinary protein levels with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA) limits renal function decline to the point that remission of disease and regression of renal lesions have been observed in experimental animals and in humans. This therapy, however, may not be effective in all patients. For patients who do not achieve complete remission of proteinuria, renoprotective treatment should include intensified blood pressure control (and metabolic control in diabetes) and amelioration of dyslipidemia. Early intervention, before progressive glomerulosclerosis and scarring is initiated by increased protein traffic, may be important to maximize reno- and cardioprotection, especially in diabetes.
引用
收藏
页码:160 / 165
页数:6
相关论文
共 28 条
[1]   Blood pressure control and nephroprotection in diabetes [J].
Abbott, K ;
Basta, E ;
Bakris, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (04) :431-438
[2]   THERAPEUTIC ADVANTAGE OF CONVERTING ENZYME-INHIBITORS IN ARRESTING PROGRESSIVE RENAL-DISEASE ASSOCIATED WITH SYSTEMIC HYPERTENSION IN THE RAT [J].
ANDERSON, S ;
RENNKE, HG ;
BRENNER, BM .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (06) :1993-2000
[3]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[4]   RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY [J].
BJORCK, S ;
MULEC, H ;
JOHNSEN, SA ;
NORDEN, G ;
AURELL, M .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823) :339-343
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   THE COMBINATION OF LOVASTATIN AND ENALAPRIL IN A MODEL OF PROGRESSIVE RENAL-DISEASE [J].
BROUHARD, BH ;
TAKAMORI, H ;
SATOH, S ;
INMAN, S ;
CRESSMAN, M ;
IRWIN, K ;
BERKLEY, V ;
STOWE, N .
PEDIATRIC NEPHROLOGY, 1994, 8 (04) :436-440
[7]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[8]  
LEE SK, 1993, NEPHROL DIAL TRANSPL, V8, P1338
[9]   THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].
LEWIS, EJ ;
HUNSICKER, LG ;
BAIN, RP ;
ROHDE, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462
[10]   Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention [J].
Macconi, D ;
Abbate, M ;
Morigi, M ;
Angioletti, S ;
Mister, M ;
Buelli, S ;
Bonomelli, M ;
Mundel, P ;
Endlich, K ;
Remuzzi, A ;
Remuzzi, G .
AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (04) :1073-1085